Citations

Clear

3138 citation(s) found for "Smith, AM".

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A P
Borate, Uma , Li, Rui , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Foran, James M. , Baer, Maria R. , Odenike, Olatoyosi , Patel, Prapti A. , Collins, Robert H. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Arellano, Martha , Blum, William , Schiller, Gary J. , Boyiadzis, Michael , Redner, Robert L. , Al‐Mansour, Zeina , Curran, Emily , Heerema, Nyla A. , Gana, Theophilus J. , Martycz, Molly , Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O. , Stefanos, Mona , Druggan, Franchesca , Burd, Amy , Byrd, John C. , Byrd, John C , Traer, Elie , Duong, Vu H. , Stock, Wendy , Madanat, Yazan F. , Smith, Catherine C. , Lin, Tara L. , Foster, Matthew C , Chen, Timothy Frank , Levine, Ross L. , Druker, Brian J , Mims, Alice S

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6200-6203

10.1182/blood-2022-167316 Get It

Development and application of a computable genotype model in the GA4GH Variation Representation Specification
Goar, Wesley , Babb, Lawrence , Cline, Melissa , Kuzma, Kori , Lee, Jennifer , Nelson, Tristan , Smith, Anastasia , Stahl, Kathryn , Bratulin, Anastasia L. , Babb, Lawrence , Chamala, Srikar , Freimuth, Robert R. , Hart, Reece K. , Prlić, Andreas , Riehle, Kevin P. , Yates, Andrew , Rehm, Heidi L. , Wagner, Alex H.

Mayo Clinic

Biocomputing 2023 | November 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: 383-394

10.1142/9789811270611_0035 Get It

Quantifying muscle blood flow: a transformative breakthrough in the science of human exercise physiology
Olson, Thomas P. , Smith, Joshua R. , Curry, Timothy B. , Smith, Joshua R

Mayo Clinic

Clinical Science | November 18, 2022 | Volume: 136 | Issue: 22 | Pages: 1653-1656

10.1042/cs20220101 | PMID 36398719 Get It

Abstract Over 50 years ago, John Wahren and Lennart Jorfeldt published a manuscript in Clinical Science where they detailed a series of studies of leg blood flow during exercise. They used a novel approach to indicator dye dilution: continuous arterial infusions of dye using venous samples. This technique allowed them to describe for the first time the fundamental relationships between large muscle group exercise, muscle blood flow, and pulmonary and muscle oxygen uptake. They also defined mechanical efficiency, a key measurement of muscle function. This paper formed the basis for research into muscle blood flow and exercise in health and disease and continued to be cited by modern research. In this commentary, we describe the innovations they made, the key observations that came out of their results, and the importance of this manuscript to current research.
Changes in Glomerular Volume, Sclerosis, and Ischemia at 5 Years after Kidney Transplantation: Incidence and Correlation with Late Graft Failure
Đenić, Aleksandar , Bogojevic, Marija , Subramani, Rashmi , Smith, Byron H. , Alexander, Mariam P., Grande, Joseph P. , Kukla, Aleksandra , Bentall, Andrew , Alexander, Mariam P. , Smith, Byron , Alexander, Mariam P , Grande, Joseph P , Kukla, Aleksandra , Bentall, Andrew , Rule, Andrew D , Denic, Aleksandar , Park, Walter D. , Schinstock, Carrie A. , Rule, Andrew D. , Stegall, Mark D.

Mayo Clinic

Journal of the American Society of Nephrology | November 17, 2022 | Volume: 34 | Issue: 2 | Pages: 346-358

10.1681/asn.2022040418 | PMID 36396330 Get It

Significance Statement Glomerular volume, ischemic glomeruli, and global glomerulosclerosis are not consistently assessed on kidney transplant biopsies. The authors evaluated morphometric measures of glomerular volume, the percentage of global glomerulosclerosis, and the percentage of ischemic glomeruli and assessed changes in these measures over time to determine whether such changes predict late allograft failure. All three features increased from transplant to five-year biopsy. Kidneys with smaller glomeruli at 5 years had more global glomerulosclerosis and a higher percentage of ischemic-appearing glomeruli. Smaller glomeruli and increasing percentages of global glomerulosclerosis and ischemic glomeruli at 5 years predicted allograft failure. Only increased percentage of ischemic glomeruli predicted allograft failure at 5 years independent of all Banff scores. Glomerular changes reflect pathologic processes that predicted allograft loss; measuring them quantitatively might enhance the current Banff system and provide biomarkers for intervention trials. Background Histology can provide insight into the biology of renal allograft loss. However, studies are lacking that use quantitative morphometry to simultaneously assess changes in mean glomerular volume and in the percentages of globally sclerosed glomeruli (GSG) and ischemic-appearing glomeruli in surveillance biopsies over time to determine whether such changes are correlated with late graft failure. Methods We used digital scans of surveillance biopsies (at implantation and at 1 and 5 years after transplantation) to morphometrically quantify glomerular volume and the percentages of GSG and ischemic-appearing glomeruli in a cohort of 835 kidney transplants. Cox proportional hazards models assessed the risk of allograft failure with these three glomerular features. Results From implantation to 5 years, mean glomerular volume increased by nearly 30% (from 2.8×10 6 to 3.6×10 6 µm 3 ), mean percentage of GSG increased from 3.2% to 13.2%, and mean percentage of ischemic-appearing glomeruli increased from 0.8% to 9.5%. Higher percentages of GSG and ischemic-appearing glomeruli at 5-year biopsy predicted allograft loss. The three glomerular features at 5-year biopsy were related; the percentage of GSG and the percentage of ischemic glomeruli were positively correlated, and both were inversely correlated to glomerular volume. At 5 years, only 5.3% of biopsies had ≥40% ischemic glomeruli, but 45% of these grafts failed (versus 11.6% for <40% ischemic glomeruli). Higher Banff scores were more common with increasing percentages of GSG and ischemia, but at 5 years, only the percentage of ischemic glomeruli added to predictive models adjusted for Banff scores. Conclusions Glomerular changes reflect important pathologic processes that predict graft loss. Measuring glomerular changes quantitatively on surveillance biopsies, especially the proportion of ischemic-appearing glomeruli, may enhance the current Banff system and be a useful surrogate end point for clinical intervention trials. Podcast This article contains a podcast at
Recipient outcomes of donor-derived glomerular fibrin thrombi in deceased donor kidney transplants
Nair, S. , Ryan, Margaret , Heilman, Raymond L. , Reddy, Kunnam, Budhiraja, Pooja , Smith, Maxwell L.

Mayo Clinic

Korean Journal of Transplantation | November 14, 2022 | Volume: 36 | Issue: 1 | Pages: S355-S355

10.4285/atw2022.f-4980 Get It

TMIC-58. PATTERNS OF CELLULAR SUBPOPULATION COHABITATION DEFINE GLIOBLASTOMA STATES
Bond, Kamila M. , Urcuyo, Javier , León, Gustavo De , Sereduk, Christopher, Singleton, Kyle , Langworthy, Jazlynn , Krishna, Chandan , Zimmerman, Richard S. , Patra, Devi Prasad, Smith, Kris A. , Donev, Kliment , Baxter, Leslie A., Mrugała, Maciej M. , Hu, Leland , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Curtin, Lee , Hawkins‐Daarud, Andrea , Leon, Gustavo De, Sereduk, Chris , Jackson, Pamela , Bendok, Bernard R. , Nakaji, Peter , Baxter, Leslie, Al‐Dalahmah, Osama , Tran, Nhan L. , Rubin, Joshua B

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii284-vii284

10.1093/neuonc/noac209.1102 Get It

Abstract Characterizing intra- and inter-tumoral heterogeneity of glioblastoma has historically relied on discrete classifications of malignant cell populations leaving immune and other cell populations, known to exist admixed with the malignant tumor cells, relatively neglected. Manifold learning algorithms can manage deconvolving multiple cell populations and are often used to track cell state transitions in single cell transcriptomics. We applied a manifold learning approach to TCGA microarray data (Nf525) and bulk transcriptomics of 134 image localized biopsies across 30 patients with primary and 9 with recurrent glioblastoma to further elucidate how to organize biopsies across a spectrum of possible tissue states. The algorithm revealed a low-dimensional manifold graph for which each biopsy lives across 3 polarizing tissue states - one that is associated with diffusely invaded brain, one that is enriched in mesenchymal genes, and one that is enriched in classical proliferative tumor signatures. We deconvolved the bulk transcriptomics of the image-localized biopsies to reveal the relative abundance of 18 malignant, immune, and other cell subpopulations in each biopsy. Overlaying the cellular decomposition onto the manifold graph visualizing the tissue state distributions revealed that transitions between states correlate with changes in cellular cohabitation composition. The tumor cellular cohabitation ecologies have the lowest diversity, as inferred by ecological measures such as Shannon entropy and evenness, at the distal poles of the graph when compared to the transitional arms. Further, we found that the relationship between imaging appearance of contrast enhancement on T1-weighted MRI and the biopsy cellular composition varies with sex and primary vs recurrent biopsy status. The limited spectrum of possible tissue states revealed by the manifold learning is suggestive of a limited continuum along which tumor and non-tumoral cell populations can cohabitate. Such a limited low-dimensional biological space may constrain the dynamics of tumor biology in a predictable manner.
SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA
Prabhu, Sujit S. , Rao, Ganesh , Laxton, Adrian W. , O’Brien, Barbara , Sloan, Andrew, Chiang, Veronica , Mohammadi, Alireza M. , Chen, Clark, Sun, David, Sinicrope, Kaylyn, Campian, Jian , Kurz, Sylvia C. , Smith, Kris A. , Tovar-Spinoza, Zulma , Leuthardt, Eric C. , Groot, John de , Kim, Albert Sungsoo , Fecci, Peter E. , Tatter, Stephen B. , Placantonakis, Dimitris G. , Strowd, Roy E. , Hadjipanayis, Costas G. , Khasraw, Mustafa , Piccioni, David Eric , Williams, Brian J.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii256-vii257

10.1093/neuonc/noac209.989 Get It

Abstract Treatment options for glioblastoma remain limited, particularly for those who are not eligible for traditional resection, whether due to lesion location or inability to tolerate open craniotomy. Maximal-safe resection followed by radiation with concurrent and adjuvant temozolomide offers the best outcomes for patients. Unfortunately, not all tumors are amenable to conventional surgical resection at the time of diagnosis with only about 1/3 of patients able to receive a gross-total resection and 15-25% of patients receiving biopsy only, thus reducing their projected overall survival to 9 months. Laser interstitial thermal therapy (LITT) is a minimally invasive, cytoreductive tool, that has demonstrated safety as a surgical approach to treat primary brain tumors. METHODS Data from LAANTERN prospective multicenter registry (NCT02392078) was analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma (N=89). Demographics, intraprocedural data, adverse events, KPS, health-economics, and survival data were prospectively collected then analyzed separately for newly diagnosed GBM (N=29) and recurrent GBM (N=60). RESULTS Median overall-survival was 9.73 months (95% CI: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 (6.94, 12.36) months for recurrent patients. Median overall-survival for newly diagnosed patients receiving post-LITT chemoradiotherapy was 16.14 months (6.11, not reached). The median length of hospital stay was 50 hours and 80% of patients were discharged to home. CONCLUSIONS LITT offers an effective cytoreductive approach for patients with newly diagnosed and recurrent IDH wild-type glioblastoma. Importantly, its use in newly diagnosed patients who receive post-LITT chemoradiotherapy leads to a median OS similar to that of patients treated with conventional surgical resection. LITT remains an important alternative for patients with inoperable tumors or those not amenable to resection. Enrollment in LAANTERN is ongoing and these cohorts will be revisited as data continues to mature. Benefits beyond cytoreduction are also being actively explored.
Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children
Berbert, Laura , Dallas, Johnathan, Newhams, Margaret M. , Chen, Sabrina , Ardoin, Stacy P. , Basiaga, Matthew L. , Crandall, Hillary , Dhakal, Sanjeev, Sagcal‐Gironella, Anna Carmela P. , Huie, Livie , Jones, Madelyn, Kim, Susan , Lionetti, Geraldina, Mannion, Melissa L. , Muscal, Eyal , Tejtel, S. Kristen Sexson , Villacis-Nunez, D. Sofia , Wu, Eveline Y. , Zambrano, Laura D. , Campbell, Angela P. , Patel, Manish M. , Randolph, Adrienne G. , Investigators, Overcoming COVID-19, Kong, Michele , Tarquinio, Keiko M. , Kücükak, Suden, FitzGerald, Madyson M., Worden, Julie, Levy, Emily R. , Martin, Lora , Malloch, Lacy , Clouser, Katharine N. , Walker, Tracie C. , Hall, Mark W., Staat, Mary Allen , Loftis, Laura L. , Smith, Lincoln , Feldstein, Leora R. , Jackson, Ashley , Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Mannion, Melissa L , Staat, Mary A , Son, Mary Beth F. , Young, Cameron C. , Canny, Susan , Dhanrajani, Anita D. , Hobbs, Charlotte V. , James, Karen, Prahalad, Sampath , Schulert, Grant S , Investigators, Overcoming COVID-19, Cvijanovich, Natalie Z , Zinter, Matt S. , Schwartz, Stephanie P. , Hall, Mark W. , McGuire, John K. , Tenforde, Mark W.

Mayo Clinic

JAMA Network Open | November 11, 2022 | Volume: 5 | Issue: 11 | Pages: e2241622

10.1001/jamanetworkopen.2022.41622 | PMID 36367723 Get It

ImportanceMinimal data are available regarding the postdischarge treatment of multisystem inflammatory syndrome in children (MIS-C).ObjectivesTo evaluate clinical characteristics associated with duration of postdischarge glucocorticoid use and assess postdischarge clinical course, laboratory test result trajectories, and adverse events in a multicenter cohort with MIS-C.Design, Setting, and ParticipantsThis retrospective cohort study included patients with MIS-C hospitalized with severe illness and followed up for 3 months in an ambulatory setting. Patients younger than 21 years who were admitted between May 15, 2020, and May 31, 2021, at 13 US hospitals were included. Inclusion criteria were inpatient treatment comprising intravenous immunoglobulin, diagnosis of cardiovascular dysfunction (vasopressor requirement or left ventricular ejection fraction ≤55%), and availability of complete outpatient data for 3 months.ExposuresGlucocorticoid treatment.Main Outcomes and MeasuresMain outcomes were patient characteristics associated with postdischarge glucocorticoid treatment, laboratory test result trajectories, and adverse events. Multivariable regression was used to evaluate factors associated with postdischarge weight gain (≥2 kg in 3 months) and hyperglycemia during illness.ResultsAmong 186 patients, the median age was 10.4 years (IQR, 6.7-14.2 years); most were male (107 [57.5%]), Black non-Hispanic (60 [32.3%]), and Hispanic or Latino (59 [31.7%]). Most children were critically ill (intensive care unit admission, 163 [87.6%]; vasopressor receipt, 134 [72.0%]) and received inpatient glucocorticoid treatment (178 [95.7%]). Most were discharged with continued glucocorticoid treatment (173 [93.0%]); median discharge dose was 42 mg/d (IQR, 30-60 mg/d) or 1.1 mg/kg/d (IQR, 0.7-1.7 mg/kg/d). Inpatient severity of illness was not associated with duration of postdischarge glucocorticoid treatment. Outpatient treatment duration varied (median, 23 days; IQR, 15-32 days). Time to normalization of C-reactive protein and ferritin levels was similar for glucocorticoid duration of less than 3 weeks vs 3 or more weeks. Readmission occurred in 7 patients (3.8%); none was for cardiovascular dysfunction. Hyperglycemia developed in 14 patients (8.1%). Seventy-five patients (43%) gained 2 kg or more after discharge (median 4.1 kg; IQR, 3.0-6.0 kg). Inpatient high-dose intravenous and oral glucocorticoid therapy was associated with postdischarge weight gain (adjusted odds ratio, 6.91; 95% CI, 1.92-24.91).Conclusions and RelevanceIn this multicenter cohort of patients with MIS-C and cardiovascular dysfunction, postdischarge glucocorticoid treatment was often prolonged, but clinical outcomes were similar in patients prescribed shorter courses. Outpatient weight gain was common. Readmission was infrequent, with none for cardiovascular dysfunction. These findings suggest that strategies are needed to optimize postdischarge glucocorticoid courses for patients with MIS-C.